Current status and perspectives of immune-based therapies for hepatocellular carcinoma by Aerts, Maridi et al.
Maridi Aerts, Hendrik Reynaert, University hospital, UZ Brussel, 
Department of Gastroenterology and Hepatology, 1090 Brussels, 
Belgium
Daphné Benteyn, Kris Thielemans, Vrije Universiteit Brussel 
(VUB), Department of Immunology, 1090 Brussels, Belgium
Hans Van Vlierberghe, UZ Gent, Department of Gastroenterology 
and Hepatology, De Pinte laan, 9000 Ghent, Belgium
Author contributions: Aerts M, Benteyn D and Reynaert H 
analyzed the literature and wrote the manuscript; Van Vlierberghe 
H and Thielemans K critically revised the manuscript.; all authors 
approved the final version of the manuscript.
Supported by Grant from Kankerplan Action 29, Ministry 
of health, Belgium (to Aerts M); Van Vlierberghe H is senior 
researcher of the Flemish Fund for Research (FWO).
 
Conflict-of-interest statement: The authors have no conflict of 
interest to report.
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Correspondence to: Hendrik Reynaert, MD, PhD, Professor, 
University hospital, UZ Brussel, Department of Gastroenterology 
and Hepatology, Laarbeeklaan 101, 1090 Brussels, 
Belgium. hendrik.reynaert@uzbrussel.be
Telephone: +32-2-4776811
Fax: +32-2-4776810
Received: June 8, 2015
Peer-review started: June 11, 2015
First decision: July 14, 2015
Revised: August 11, 2015
Accepted: October 26, 2015 
Article in press: October 26, 2015
Published online: January 7, 2016
Abstract
Hepatocellular carcinoma (HCC) is a frequent cancer 
with a high mortality. For early stage cancer there 
are potentially curative treatments including local 
ablation, resection and liver transplantation. However, 
for more advanced stage disease, there is no optimal 
treatment available. Even in the case of a “curative” 
treatment, recurrence or development of a new cancer 
in the precancerous liver is common. Thus, there is 
an urgent need for novel and effective (adjuvant) 
therapies to treat HCC and to prevent recurrence 
after local treatment in patients with HCC. The 
unique immune response in the liver favors tolerance, 
which remains a genuine challenge for conventional 
immunotherapy in patients with HCC. However, 
even in this “immunotolerant” organ, spontaneous 
immune responses against tumor antigens have been 
detected, although they are insufficient to achieve 
significant tumor death. Local ablation therapy 
leads to immunogenic tumor cell death by inducing 
the release of massive amounts of antigens, which 
enhances spontaneous immune response. New 
immune therapies such as dendritic cell vaccination and 
immune checkpoint inhibition are under investigation. 
Immunotherapy for cancer has made huge progress in 
the last few years and clinical trials examining the use 
of immunotherapy to treat hepatocellular carcinoma 
have shown some success. In this review, we discuss 
the current status of and offer some perspectives on 
immunotherapy for hepatocellular carcinoma, which 
could change disease progression in the near future.
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Core tip: Hepatocellular carcinoma is a frequent cancer 
with a high mortality. For early stage cancer there 
are potentially curative treatments including local 
ablation, resection and liver transplantation. However, 
recurrence or development of a new tumor after 
treatment are not uncommon. Moreover, for more 
advanced stage disease, there is no optimal treatment 
available. Thus, there is an urgent need for novel and 
effective therapies for advanced stage hepatocellular 
carcinoma, and to prevent and to treat recurrence after 
local treatment of hepatocellular carcinoma.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most 
common and fatal cancers in the world. Men are more 
often affected than women, with 554000 and 228000 
new cases per year, respectively. It is the second 
most common cause of death from cancer worldwide, 
leading to 746000 deaths in 2012. Viral hepatitis B and 
C, chronic alcohol consumption and non-alcoholic fatty 
liver disease are major risk factors[1].
Once diagnosed, HCC frequently has a dismal 
prognosis because of the low effectiveness of available 
treatments. The choice of treatment is selected 
according to the Barcelona Clinic Liver Cancer staging 
system, which integrates tumor characteristics and 
performance status with liver function and links them 
to evidence-based therapeutic option[2]. Early and 
very early stage tumors are potentially curable with 
surgery (resection or liver transplantation) or local 
therapies including radiofrequency ablation (RFA) or 
percutaneous ethanol injection. The 5 year survival 
rate in these patients ranges from 40% to 70%[2]. In 
the absence of liver transplantation, tumor recurrence 
is observed in 70% of patients after resection or RFA 
after a time period of 3 years. Unfortunately, less than 
30% of HCC patients are eligible for these procedures 
because most have intermediate or advanced stage 
disease at diagnosis (large or multifocal tumors, or liver 
insufficiency, which limits treatment). For intermediate 
stage tumors, transarterial chemoembolization (TACE) 
(conventional or drug eluting beads) has become the 
standard of care[3]. However, there is certainly room for 
improvement because the 3-year survival rate is only 
approximately 60%[4,5]. In advanced stage disease, 
the oral multi-targeted kinase inhibitor sorafenib offers 
a survival benefit of approximately 3 mo[6]. Other 
molecules, such as sunitinib or linifanib have not been 
proven to be superior to sorafenib[7,8]. Several newer 
molecules have been shown to confer a survival 
advantage in a subset of patients[9]. The mean survival 
of patients with advanced stage HCC is less than 1 
year. 
Recurrence rates remain high in very early to 
intermediate stages despite the availability of poten-
tially curative treatment. There are 2 main reasons 
responsible for this phenomenon. First, a small 
tumor that is undetectable using current imaging 
modalities may exist before treatment and would 
thus be left untreated; second, a new tumor may 
occur in the diseased liver, which can be considered a 
pre-neoplastic organ. The efficacy of combining local 
treatment with systemic treatment has been studied 
in several clinical trials. In phase Ⅰ and Ⅱ trials, the 
preliminary results from using combination therapies 
were promising. However, two large multicenter phase 
Ⅲ trials studying the effect of sorafenib after TACE 
(SPACE study)[10] or surgical resection/RFA (STORM 
study)[11] failed to demonstrate any adjuvant effect 
of sorafenib on survival. This underlines the need 
for novel and effective adjuvant therapies to treat 
patients with HCC and to prevent recurrence after local 
treatment. 
IMMUNE RESPONSE IN THE LIVER AND 
IMMUNOTHERAPY
The liver is a unique organ in several ways, one 
of which is its blood supply. Approximately 25% 
and 75% of the blood enters the liver through the 
hepatic artery and portal vein, respectively[12]. After 
a meal, the percentage of the portal vein supply 
increases further. The portal vein drains into smaller 
diameter structures, known as the sinusoids. Vascular 
resistance is very low in these structures, and portal 
venous blood, which is loaded with food and microbial 
antigens from the intestine, flows extremely slowly in 
the sinusoids. Moreover, liver sinusoidal cells (LSECs) 
are fenestrated thus facilitating the passage of cells 
and antigens between the sinusoids and the space of 
Disse, which is in contact with hepatocytes. With the 
exception of hepatocytes and biliary cells, the liver 
hosts a number of non-parenchymal cells including 
LSECs, hepatic stellate cells, Kupffer cells, dendritic 
cells (DCs), and lymphocytes. All of these cells play 
roles in the barrier function of the liver, separating it 
from the gastrointestinal tract and the rest of the body. 
Indeed, DCs, LSECs, hepatic stellate cells and Kupffer 
cells are all able to present antigens to antigen-specific 
lymphocytes. These cells are resident cells and induce 
tolerance rather than immunity. For a more detailed 
discussion of the immunological properties of the liver, 
we refer the reader to several recent, excellent reviews 
on this topic[13-15].
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Immunotherapy for cancer is based on harnessing 
the potential of the immune system to destroy 
malignant cells. However, immune responses in the 
liver might be problematic, as the liver mainly induces 
tolerance. The liver is a distinctive organ with respect 
to immune function and possesses a unique form 
of immune regulation: immune tolerance is induced 
to avoid chronic inflammation caused by antigens 
present in portal vein blood. This might prevent an 
adequate immune response against malignant cells. 
Indeed, it has been shown that an increased quantity 
of circulating regulatory T (Treg) cells in patients 
with HCC is associated with a high mortality rate 
and reduced survival[16]. Overcoming this immune 
tolerance is thus an important challenge in the search 
for an effective immunotherapy against HCC. On the 
other hand, there have been reports of spontaneous 
regression of HCC associated with tumor hypoxia or 
systemic inflammatory response[17]. Additionally, the 
regression of HCC has been described following the 
discontinuation of immunosuppressive therapy[18]. 
Therefore, immunotherapy remains an attractive 
approach for boosting the immune system in patients 
with HCC to enhance the efficacy of current therapies 
(Figure 1).
SPONTANEOUS TUMOR-SPECIFIC 
IMMUNE RESPONSE IN THE LIVER 
Immune evasion is a characteristic of cancer and is even 
more prevalent in organs with high immune tolerance 
such as the liver. High levels of CD4+CD25+FOXP3+ Treg 
cells in peripheral blood are an independent predictive 
factor of poor survival after TACE treatment in patients 
with HCC[19]. In addition, the presence of high numbers 
of intrahepatic CD8+FoxP3+ regulatory T cells was found 
to be associated with more advanced stages of HCC[20]. 
Additionally, there is an increased presence of myeloid-
derived suppressor cells is increased in patients with 
HCC compared to healthy donors[21].
Even if HCC is not generally considered an “immu-
nogenic” tumor type, immune responses do occur in 
livers that have been invaded by HCC. In a number 
of patients, spontaneous immune responses against 
tumor antigens have been detected, but these 
were insufficient to achieve a significant therapeutic 
effect[22-24]. Moreover, naturally occurring tumor-
associated antigen-specific T-cell responses exist in 
patients with HCC and correlate with patient survival[25]. 
Patients whose tumors express multiple tumor-
associated antigens (TAAs) and contain TAA-specific 
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Figure 1  Immune-based therapies for hepatocellular carcinoma. Tumor-specific T cells can be stimulated by several ways including adoptive cell therapy, tumor 
vaccines, cytokines or by inhibiting immune suppressive mechanisms (immune checkpoint inhibitors, depletion of Tregs or MDSCs). These tumor-specific T cells are 
able to kill the tumor cells in an antigen-specific way. Conventional therapies (RFA, TACE, PEI, microwave ablation, TARE) can destroy tumor cells, which result in the 
release of tumor antigens and danger-associated molecular patterns that can activate DCs resulting in the activation of tumor-specific T cells. RFA: Radiofrequency 
ablation; PEI: Percutaneous ethanol injection; TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization; DAMPs: Danger-associated molecular 
patterns; PAMPs: Pathogen-associated molecular patterns; DC: Dendritic cell; NK: Natural killer; LAK: Lymphokine-activated killer; NKT cell: Natural killer T cell; CIK: 
Cytokine-induced killer; CAR: Chimeric antigen receptor; CTL: Cytotoxic T lymphocyte; Treg: Regulatory T cell; MDSC: Myeloid derived suppressor cells; CTLA-4: 
Cytotoxic T lymphocyte antigen 4; PD-1: Programmed-death 1.
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are dysfunctional, regulatory T cells reduce immune 
response, and tumor cells have acquired mutations, 
allowing them to escape the immune response. This 
phenomenon is called cancer immunoediting[38]. 
Because the immune response is inadequate, it is 
important to stimulate the immune system and avoid 
immune escape.
Ablative therapies such as TACE, cryoablation 
and RFA result in immunogenic tumor cell death by 
inducing the release of massive amounts of antigens 
together with “danger signals” from tumor cells, such 
as damage-associated molecular pattern molecules 
(DAMPs). This release leads to the activation 
of DCs and in vivo auto-immunization or in situ 
vaccination[39-41]. Increased frequencies of GPC3-
specific cytotoxic T cells were observed in patients 
after RFA and TACE treatment[33]. Hiroishi et al[42] 
studied GPC3, NY-ESO-1- and MAGE-1-specific CD8+ 
T-cell responses before and after ablative (RFA or 
TACE) treatment for HCC. They observed that the 
presence of strong TAA-specific CD8+ T-cell responses 
suppressed the recurrence of HCC and that the 
magnitude of a TAA-specific CD8+ T-cell response was 
a prognostic factor for a prolonged tumor-free interval. 
Nobuoka et al[33] reported that RFA induced a GPC3-
specific T-cell response. For the first time, they showed 
that RFA induced a stronger GPC3-specific immune 
response than surgical resection because RFA destroys 
tumor tissue and causes local necrosis followed by the 
release of tumor-associated antigens, whereas surgery 
removes almost all of tumor-associated antigens. 
From these results, it appears that immunotherapy 
to induce TAA-specific cytotoxic T lymphocytes 
after local therapy should be considered for clinical 
application in patients with HCC.
THERAPEUTIC VACCINATION FOR HCC: 
DENDRITIC CELL VACCINATION
The aim of cancer vaccination is the induction and 
perpetuation of a tumor-specific immune response by 
eliciting effector T cells that can specifically decrease 
tumor load and induce immunological memory to 
control tumor relapse. Thus, dendritic cell-based 
therapies aim to either induce new or enhance pre-
existing antigen-specific T cells, but they have no direct 
effect on tumor cells. Instead, these vaccines affect 
on different cell types of the immune system, which 
can induce tumor cell death. Once targetable tumor 
antigens have been identified, they can be used to load 
professional antigen presenting cells, i.e., DCs. DCs 
play key roles in both innate and adaptive immunity[43]. 
DCs can either be loaded in vivo or ex vivo. DCs 
capture antigens and convert them to peptides that 
are presented on major histocompatibility complex 
(MHC) molecules, which are recognized by T cells in 
lymphoid organs. In addition, RFA treatment has been 
shown to up-regulate tumor antigen expression and 
CD8+ T-cell lymphocytic infiltrates show longer survival 
rates and a lower risk of recurrence[25-27]. A strong CD8+ 
T-cell response against TAAs was shown to improve 
recurrence-free survival after surgery. 
Over the past 15 years, a number of TAAs have 
been identified in HCC, some of which elicit tumor-
specific immune responses[24]. Most of the identified 
TAAs are not specific to HCC, but some HHC-specific 
TAAs are targeted by T cells, which makes them good 
potential targets for immunotherapy; these include 
alpha-fetoprotein (AFP), glypican 3 (GPC3), melanoma 
antigen gene A (MAGE-A), and New York-esophageal 
squamous cell carcinoma-1 (NY-ESO-1)[25,28].
AFP, which is expressed in the fetus and repressed 
after birth, is re-expressed in the majority of HCCs. 
Even if it has a low sensitivity and specificity as a 
serum marker, it continues to represent a useful clinical 
marker for HCC[29]. In some studies, HCC patients had 
increased frequencies of circulating AFP-specific CD8+ 
T cells[23,30]. 
GPC3 is a cell surface heparin sulfate proteoglycan. 
GPC3 mRNA expression is low or absent in normal liver 
tissue, in benign tumor lesions (such as focal nodular 
hyperplasia) and in a cirrhotic liver[31]. However, 
GPC-3 is detected in approximately 80% of HCCs 
even in the early stages[27,32]. GPC3-specific cytotoxic 
T-lymphocytes have a high level of killing activity 
against HCC tumor cells. A study from Nobuoka et 
al[33] showed that GPC3 has strong immunogenicity.
MAGE-A was first described in melanoma, but it 
has been shown to be widely expressed in various 
tumors. In cirrhotic patients with HCC, mRNA encoding 
MAGE-1 was found to be present in 80% of resected 
HCCs[34]. MAGE-A and SSX-2 specific CD8+ T cells were 
found to be enriched in HCC, but not in surrounding 
liver tissue[35]. In healthy subjects, NY-ESO-1 is only 
expressed in testes, but it is expressed in several 
tumors, including HCC. NY-ESO-1-specific CD8+ T cells 
have also been shown to be present in HCC[36,37].
Flecken et al[25] studied the frequency and tumor-
infiltration capacity of naturally occurring CD8+ T-cell 
responses targeting AFP, GPC3, MAGE-A and NY-
ESO-1. They found antigen-specific CD8+ T-cell 
responses directed against all four TAAs in over 50% 
of the patients. Moreover, survival was significantly 
increased in patients with TAA-specific CD8+ T-cell 
response, which suggests that immunotherapy may 
be beneficial for patients with HCC. Unfortunately, they 
were unable to expand functional TAA-specific CD8+ T 
cells from HCC patients in vitro. 
ENHANCING SPONTANEOUS IMMUNE 
RESPONSE
Controlling HCC by harnessing naturally occurring, 
specific immune responses typically fails because 
the immune responses are not strong enough to 
overcome the disease. Tumor-specific CD8+ T cells 
Aerts M et al . Immune therapy for HCC
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MHC presentation in tumor cells in an in vivo mouse 
model[44]. These results suggest the effectiveness of 
combing active immunotherapy and conventional 
therapies, such as RFA, to augment tumor cell 
recognition by T cells and eventually improve clinical 
outcome.
However, both infections and tumors can suppress 
immunity through the release of cytokines, such 
as interleukin (IL)-6, vascular endothelial growth 
factor (VEGF) and IL-10, which suppress DC activity. 
Moreover, tumors may condition local DCs to form 
suppressive T cells, diminishing immune responses 
against cancer cells. In humans, immature DCs are 
capable of inducing antigen-specific regulatory CD8+ T 
cells[45]. It is therefore imperative to use mature DCs to 
avoid the immunosuppressive effects of tumor cells[46] 
or to counteract the inhibitory mechanisms of tumor 
cells when using anti-PD1/PD-L1, or anti-CTLA4, 
treatments (discussed in more detail below). Several 
strategies have been developed to accomplish this, 
including ex vivo DC activation; the addition of strong 
activation stimuli; the optimization of administered 
tumor-associated antigens; and the optimization of 
the dose, frequency and route of administration of 
a vaccine. Using these strategies, DC vaccines are 
capable of initiating strong cytotoxic T-lymphocyte 
responses against TAAs, and DC vaccination remains a 
good approach for immunotherapy of HCC[47,48].
Ex vivo-matured DCs pulsed with tumor lysate were 
injected intra-dermally into patients with advanced 
HCC. This therapy was shown to be safe, and there 
were significantly more AFP-specific CD8+ T cells 1 
mo after DC injection. There were fewer patients with 
progressive disease in the vaccinated vs in the non-
vaccinated group, and the mean patient survival was 
prolonged, although not significantly[49]. In a phase 1 
study, 10 patients were treated with radical microwave 
ablation of HCC followed by 3 courses of mature DC 
injection into the inguinal lymph nodes and the infusion 
of immature DCs into microwave-treated HCC lesions. 
No grade 3/4 toxicity was observed. The percentage 
of CD4+CD25+ regulatory T lymphocytes decreased 
significantly and the percentage of CD8+CD28- effector 
cells increased significantly by 1 mo after therapy, 
but this encouraging result disappeared by 6 mo after 
therapy[50].
In another phase 1 study, 5 patients were treated 
with TACE, followed by repeated DC vaccination. The 
vaccine was prepared by pulsing DCs with cytoplasmic 
transduction peptide-attached AFP, GPC3 and MAGE-1 
recombinant fusion proteins. Mature DCs were injected 
subcutaneously near the inguinal lymph nodes in 
combination with the application of Toll-like receptor 
7 agonist at the site of injection. In all patients, the 
vaccine was safe and elicited TAA-specific T cell 
responses. In one patient, this resulted in stable 
disease[51]. Thirty-five patients were included in a phase 
Ⅱ clinical trial investigating the safety and efficacy of 
intravenous vaccination with mature autologous DCs 
pulsed ex vivo with tumor cell lysate. Patients received 
up to 6 vaccines at 3-wk intervals. The treatment was 
safe and well tolerated, generating antigen-specific 
immune responses in some cases; unfortunately, there 
were very low clinical responses[52]. In another phase 
Ⅱ clinical trial that assessed 31 patients with advanced 
HCC, DCs were pulsed with autologous tumor lysates. 
The patients were treated with five courses of DC 
vaccination intravenously at weekly intervals and 
in 17 patients this was followed by monthly boost 
vaccinations. The treatment was safe. Among these 
31 patients, 4 had a partial response and 17 had 
stable disease. Moreover, the patients treated with the 
boosted therapy had a 1-year survival rate of 63.3% 
vs 10.7% in patients treated with the initial pulsed 
therapy alone[53]. These results are promising, but the 
overall results of DC vaccination are unsatisfactory and 
should be improved (Table 1).
One possibility for improvement could be com-
bining vaccination with anti-angiogenic tyrosine 
kinase inhibitors (TKIs), such as sorafenib. This 
strategy targets multiple components of the tumor 
microenvironment and could mediate an anti-tumor 
response by immunogenic modulation and immune 
subset conditioning[54]. Additionally, the vascular 
changes caused by TKIs affect tumor-infiltrating 
immune cells, so the combining TKIs with immune 
therapy could enhance the clinical benefit[55].
Another area of concern is the recurrence of HCC 
after liver transplantation[56]. Indeed, it has been 
shown that the recurrence rates of HCC after liver 
transplantation for HCC are high and have a dismal 
prognosis[57]. Disease progression was significantly 
faster in transplanted patients than in patients who 
underwent surgical resection of HCC, probably due to 
immunosuppression and reduced host immunity[58]. 
Immunosuppression via mammalian targets of 
rapamycin seems to decrease recurrence rates and 
Table 1  Clinical trials of immune therapy in hepatocellular 
carcinoma
Regimen Patients, 
n
Clinical response Reference
HCC vaccines
   DC's + auto-tumor 
   lysate
31 PR: 12.9%, SD: 
54.8%
Lee et al[53], 2005
   DC's + 4 AFP 
   peptides
16 No clinical 
response
Butterfield et al[30], 
2007
   DC's + HepG2 lysate 25 PR + SD: 28% Palmer et al[52], 2009
   GV 1001 + GM-CSF 40 SD: 45.9% Greten et al[71], 2010
   GPC3 peptides 33 PR: 3%, SD: 
57.6%
Sawada et al[72], 2012
   DC's 30 PR: 17%, SD: 
60%
El Ansary et al[49], 
2013
   Immune checkpoint 
   inhibitors
   Tremelimumab 21 PR: 17.6%, SD: 
58.8%
Sangro et al[62], 2013
PR: Partial response; SD: Stable disease.
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to slow progression in case of recurrence[59]. DC 
vaccination has not been tested in liver transplant 
patients, but it has been shown to be safe and 
promising with regards to immunological responses 
after allogeneic-hematopoietic cell transplantation[60].
IMMUNE CHECKPOINT BLOCKADE
The intensity of an immune response results from the 
balance between stimulatory and inhibitory signals, 
known as immune checkpoints. These checkpoints are 
often activated by tumor signals and promote tumor 
evasion from immunity. Cytotoxic T lymphocyte-
associated antigen (CTLA-4) and programmed death 1 
(PD-1) are the two most studied immune checkpoints, 
and inhibitory antibodies against these are already 
being used in clinical trials. The mechanisms of action 
of CTLA-4 and PD-1 and their possible roles in treating 
HCC were recently reviewed[61]. The CTLA-4 inhibitor, 
tremelimumab was studied in a phase 1 clinical trial. 
It was well tolerated, and 76% of the enrolled patients 
had either a partial response or stable disease, of 
which 45% were stable for more than 6 mo[62]. 
PD-1 was found in liver-infiltrating lymphocytes and 
its ligands PD-L1 and PD-L2 were shown to be up-
regulated in HCC tissue[63]. Currently, several anti-PD-1 
and anti-PD-L1 antibodies are being developed, and 
their use in clinical studies of HCC is planned.
PERSPECTIVES
Antigen-encoding mRNA is emerging as a particularly 
promising vaccination tool as it has many advantages 
to offer. Its advantage over classical vaccination with 
peptides is that RNA encodes genetic information 
corresponding to whole antigens. RNA processing 
by endogenous cell machinery and presentation on 
MHC complexes are independent of the HLA-subtype 
of a patient. In addition, RNA does not pose a risk 
of genomic integration, giving it a favorable safety 
profile compared to DNA. Due to its transient nature, 
RNA is only expressed during a controlled period of 
time and is eventually degraded into natural products. 
Furthermore, RNA acts as its own adjuvant, prompting 
co-stimulatory signals, which is advantageous in the 
context of RNA-based immunotherapy. Even hard-
to-modify cells, such as DCs can be modified with 
mRNA. Two routes for exogenous mRNA delivery into 
DCs have been applied: either ex vivo delivery with 
subsequent adoptive transfer of transfected DCs or the 
direct administration of mRNA with subsequent uptake 
in vivo. For the former, DCs derived from patients are 
cultivated and electroporated with mRNA followed by 
their restitution into the patient. 
In situ modification of DCs by immunization 
via the direct application of naked mRNA was first 
described 25 years ago[64]. Since then, several studies 
have shown anti-tumor immune responses following 
the injection of naked mRNA in a variety of mouse 
models[65]. It is assumed that intradermal delivery of 
mRNA results in its uptake by Langerhans’ cells and 
dermal DCs at the injection site, which are transported 
to draining lymph nodes. It is moreover assumed 
that these DCs transfer their antigenic cargo to lymph 
node-resident CD8+ DCs when they arrive in the 
draining lymph nodes. Direct injection of mRNA into 
lymph nodes results in the uptake of mRNA and has 
been shown to be superior to intradermal injection of 
mRNA with respect to the induction of antigen-specific 
T cell responses[65]. Currently, intranodal administration 
of mRNA is proposed as the optimal route for delivery 
because lymph nodes harbor a high number of DCs. 
Intranodal administration creates a microenvironment 
that favors the induction of potent and sustained 
immune responses. Lymph node resident dendritic 
cells up-regulate CD86, and this is required for the 
efficient activation of naïve T cells and for immunologic 
memory[66,67].
Currently, we are performing a phase 1 study inves-
tigating the feasibility and safety of the intranodal 
injection of a TriMix-based mRNA vaccine. The concept 
was studied in melanoma animal models[67]. The idea 
is to use mRNA for the in vivo modification of DCs by 
direct administration into lymph nodes, which harbor a 
high number of DCs in close contact with T cells. For a 
detailed description, we refer to our recent review[68]. 
In melanoma patients, we previously showed that 
TriMix mRNA (mRNA encoding CD40 ligand, CD70 
and a constitutively active form of TLR4), induced the 
activation of DCs, resulting in the induction of a T cell 
attracting and stimulatory environment[69]. Moreover, 
the co-administration of tumor antigen mRNA and 
TriMix resulted in the recruitment of antigen-specific 
CD4+ and CD8+ T cells. Simultaneous delivery of TriMix 
and antigen mRNA significantly enhanced the induction 
of antigen-specific T cells compared to intranodal 
delivery of antigen mRNA alone[67,68]. In the current 
study, TriMix mRNA and mRNA encoding the target 
antigens GPC3 and MAGE-C2 mRNA were injected 
intranodally the same day as RFA treatment of HCC 
thereby increasing tumor antigen load. The mRNA 
injection was repeated 3 times at 2-wk intervals. If 
this intervention appears to be safe, we plan to add 
immune checkpoint blockers, which could increase the 
efficacy of the vaccination as we showed in previous 
melanoma studies[68]. To avoid systemic autoimmune 
toxicity caused by anti-CTLA-4 or anti-PD-1 treatment, 
mRNA encoding factors that have the ability to block 
CTLA-4 or PD-1 can be used[70]. 
CONCLUSION
Hepatocellular carcinoma is a very common cancer 
with a high mortality, and the current standard 
treatment for it is unsatisfactory. Tumor recurrence 
and the development of new cancer after treatment 
is frequent and remains a major problem. Because 
immunotherapy not only treats an existing tumor, but 
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also has the potential to prevent the development of 
new cancers in the cirrhotic liver, vaccination for HCC 
remains an attractive treatment option. In this context, 
the combination of active specific immunotherapy 
with ablative therapy might be an appealing and 
feasible approach and may provide better results 
than individual treatments. Immunotherapy will be 
most effective during or shortly after ablative therapy, 
when tumor cells are dying and an active immune 
response has commenced. This first “priming” by the 
ablative therapy should be sustained by “booster”
immunizations to maintain immune control over the 
tumor. One difficulty is the immune tolerance of the 
liver, and the immunosuppressive environment of 
cancer, which makes in situ activation of immune cells 
problematic. This problem can be overcome by ex vivo 
activation of DCs or by in vivo activation of DCs in skin 
or lymph nodes. The addition of immune checkpoint 
inhibitors will undoubtedly add significantly to efficacy, 
but this will probably increase side effects.
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